Biliary Tract Cancer Market is Expected to Expand at a Healthy Growth Rate During the Forecast Period (2024-2034), States DelveInsight | AstraZeneca, Taiho Oncology, Delcath Systems, TransThera Sciences (Nanjing), Basilea Pharma, Eisai, Merck Sharp & Dohm

DelveInsight's "Biliary Tract Cancer Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Biliary Tract Cancer, historical and forecasted epidemiology as well as the Biliary Tract Cancer market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Biliary Tract Cancer market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Biliary Tract Cancer Market Forecast
https://www.delveinsight.com/sample-request/biliary-tract-cancers-btcs-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Biliary Tract Cancer Market Report:
• The Biliary Tract Cancer market size is anticipated to grow with a significant CAGR during the study period (2020-2034)
• In December 2023, RenovoRx, a clinical-stage biopharmaceutical firm, has chosen Oklahoma University (OU) Health as the inaugural study site for the Phase III CouGar Trial, investigating RenovoGem's efficacy in treating bile duct cancer, particularly unresectable locally advanced extrahepatic cholangiocarcinoma (eCCA).
• The overall number of BTC incident cases in the 7MM population in 2022 was found to be 38,000. Japan was the country with the highest number of cases of BTC cancer, followed by the US.
• Of the total number of stage-specific BTC cases in EU4 and the UK in 2022, around 89% were of Stage IV, compared to approximately 18% in Japan and approximately 37% in the US
• A total of approximately 16,000 BTC patients were treated in the US in 2022; 4,500 of these cases were localized and regional, 8,000 were first-line advanced or metastatic cases, and 3,000 were second-line and above advanced or metastatic cases.
• In Japan, around 45% of BTC patients were 80 years of age or older in 2022. In the US, about 24% of BTC patients were 80 years of age or older, and about 29% of patients were between the ages of 70 and 79.
• Key Biliary Tract Cancer Companies: Merck Sharp & Dohme, AstraZeneca, Taiho Oncology, Delcath Systems, TransThera Sciences (Nanjing), Basilea Pharmaceutica, Eisai, Zymeworks, BeiGene, Xencor, Inc., Bristol-Myers Squibb, Leap Therapeutics, Inc., Compass Therapeutics, Boehringer Ingelheim, ZielBio, Inc., GeneQuantum Healthcare (Suzhou) Co., Ltd., BioNTech SE, SOTIO Biotech, Carisma Therapeutics Inc, Rain Oncology Inc, Avacta Life Sciences Ltd, DualityBio Inc., and others
• Key Biliary Tract Cancer Therapies: Keytruda (pembrolizumab), Imfinzi (durvalumab), Futibatinib (TAS-120), Melphalan, E7090 (tasurgratinib), TT-00420, ARQ 087 (Derazantinib), Lenvima (lenvatinib), Zanidatamab, XmAb20717, Nivolumab + DKN-01, CTX-009, MEDI5752, Brigimadlin, ZB131, GQ1001, BNT141, SO-C101, CT-0508, RAIN-32, AVA6000, DB-1303, and others
• The Biliary Tract Cancer market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Biliary Tract Cancer pipeline products will significantly revolutionize the Biliary Tract Cancer market dynamics.

Biliary Tract Cancer Overview
Biliary tract cancer, also known as cholangiocarcinoma, is a type of cancer that originates in the bile ducts, which are small tubes that carry bile from the liver to the small intestine. This cancer can occur anywhere along the bile ducts, from the liver (intrahepatic) to the small intestine (extrahepatic). Biliary tract cancer is relatively rare but can be aggressive and difficult to treat, especially if it is not diagnosed until later stages.

Get a Free sample for the Biliary Tract Cancer Market Report:
https://www.delveinsight.com/report-store/biliary-tract-cancers-btcs-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Biliary Tract Cancer Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Biliary Tract Cancer Epidemiology Segmentation:
The Biliary Tract Cancer market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Total Prevalence of Biliary Tract Cancer
• Prevalent Cases of Biliary Tract Cancer by severity
• Gender-specific Prevalence of Biliary Tract Cancer
• Diagnosed Cases of Episodic and Chronic Biliary Tract Cancer

Download the report to understand which factors are driving Biliary Tract Cancer epidemiology trends @ Biliary Tract Cancer Epidemiology Forecast
https://www.delveinsight.com/sample-request/biliary-tract-cancers-btcs-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Biliary Tract Cancer Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Biliary Tract Cancer market or expected to get launched during the study period. The analysis covers Biliary Tract Cancer market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Biliary Tract Cancer Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Biliary Tract Cancer Therapies and Key Companies
• Keytruda (pembrolizumab): Merck Sharp & Dohme
• Imfinzi (durvalumab): AstraZeneca
• Futibatinib (TAS-120): Taiho Oncology
• Melphalan: Delcath Systems
• E7090 (tasurgratinib): Eisai
• TT-00420: TransThera Sciences (Nanjing)
• ARQ 087 (Derazantinib): Basilea Pharmaceutica
• Lenvima (lenvatinib): Eisai and Merck & Co
• Zanidatamab: Zymeworks and BeiGene
• XmAb20717: Xencor, Inc.
• Nivolumab + DKN-01: Bristol-Myers Squibb/Leap Therapeutics, Inc.
• CTX-009: Compass Therapeutics
• MEDI5752: AstraZeneca
• Brigimadlin: Boehringer Ingelheim
• ZB131: ZielBio, Inc.
• GQ1001: GeneQuantum Healthcare (Suzhou) Co., Ltd.
• BNT141: BioNTech SE
• SO-C101: SOTIO Biotech
• CT-0508: Carisma Therapeutics Inc
• RAIN-32: Rain Oncology Inc
• AVA6000: Avacta Life Sciences Ltd
• DB-1303: DualityBio Inc.

Discover more about therapies set to grab major Biliary Tract Cancer market share @ Biliary Tract Cancer Treatment Market
https://www.delveinsight.com/sample-request/biliary-tract-cancers-btcs-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Biliary Tract Cancer Market Strengths
• The therapeutic landscape in BTCs has expanded considerably in recent years. Combined therapy with chemotherapy, immunotherapy, and modulation of immune checkpoints-mediated signaling pathways are promising strategies.

Biliary Tract Cancer Market Opportunities
• Increasing cognizance about different mutations, pathways, and other regimens has changed the focus on curable treatment options with emerging candidates that will lead the growth of the global market.

Scope of the Biliary Tract Cancer Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Biliary Tract Cancer Companies: Merck Sharp & Dohme, AstraZeneca, Taiho Oncology, Delcath Systems, TransThera Sciences (Nanjing), Basilea Pharmaceutica, Eisai, Zymeworks, BeiGene, Xencor, Inc., Bristol-Myers Squibb, Leap Therapeutics, Inc., Compass Therapeutics, Boehringer Ingelheim, ZielBio, Inc., GeneQuantum Healthcare (Suzhou) Co., Ltd., BioNTech SE, SOTIO Biotech, Carisma Therapeutics Inc, Rain Oncology Inc, Avacta Life Sciences Ltd, DualityBio Inc., and others
• Key Biliary Tract Cancer Therapies: Keytruda (pembrolizumab), Imfinzi (durvalumab), Futibatinib (TAS-120), Melphalan, E7090 (tasurgratinib), TT-00420, ARQ 087 (Derazantinib), Lenvima (lenvatinib), Zanidatamab, XmAb20717, Nivolumab + DKN-01, CTX-009, MEDI5752, Brigimadlin, ZB131, GQ1001, BNT141, SO-C101, CT-0508, RAIN-32, AVA6000, DB-1303, and others
• Biliary Tract Cancer Therapeutic Assessment: Biliary Tract Cancer current marketed and Biliary Tract Cancer emerging therapies
• Biliary Tract Cancer Market Dynamics: Biliary Tract Cancer market drivers and Biliary Tract Cancer market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Biliary Tract Cancer Unmet Needs, KOL's views, Analyst's views, Biliary Tract Cancer Market Access and Reimbursement

To know more about Biliary Tract Cancer companies working in the treatment market, visit @ Biliary Tract Cancer Clinical Trials and Therapeutic Assessment
https://www.delveinsight.com/sample-request/biliary-tract-cancers-btcs-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Biliary Tract Cancer Market Report Introduction
2. Executive Summary for Biliary Tract Cancer
3. SWOT analysis of Biliary Tract Cancer
4. Biliary Tract Cancer Patient Share (%) Overview at a Glance
5. Biliary Tract Cancer Market Overview at a Glance
6. Biliary Tract Cancer Disease Background and Overview
7. Biliary Tract Cancer Epidemiology and Patient Population
8. Country-Specific Patient Population of Biliary Tract Cancer
9. Biliary Tract Cancer Current Treatment and Medical Practices
10. Biliary Tract Cancer Unmet Needs
11. Biliary Tract Cancer Emerging Therapies
12. Biliary Tract Cancer Market Outlook
13. Country-Wise Biliary Tract Cancer Market Analysis (2020-2034)
14. Biliary Tract Cancer Market Access and Reimbursement of Therapies
15. Biliary Tract Cancer Market Drivers
16. Biliary Tract Cancer Market Barriers
17. Biliary Tract Cancer Appendix
18. Biliary Tract Cancer Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Latest Reports Offered By DelveInsight:

Ventilator Market
https://www.delveinsight.com/report-store/ventilators-market
Ventilators Market By Mobility (Intensive Care Ventilators, Portable/Transportable Ventilators), By Type (Adult/Pediatric Ventilators, Neonatal/Infant Ventilators), By Interface (Invasive Ventilation, Non-Invasive Ventilation), By End-User (Hospitals, Home Care, Ambulatory Surgical Centers, Others), By Geography is expected to grow at a steady CAGR forecast till 2028 owing to launch of advanced devices and increasing prevalence of respiratory diseases such as COPD.

Vascular Graft Devices Market
https://www.delveinsight.com/report-store/vascular-grafts-market
Vascular Graft Devices Market By Product Type (Endovascular Grafts [Abdominal And Thoracic], Access Grafts, Peripheral Grafts, And Others), By Type (Knitted, Woven, And Others), By Material (Synthetic[ Polytetrafluoroethylene [PTFE], Polyester, Polyurethane], Biological, And Others), By End User (Hospitals, Ambulatory Surgical Centers, And Others), by geography is expected to register commendable revenue growth at a steady CAGR forecast till 2028 owing to increasing prevalence of cardiovascular diseases such as aortic aneurysms and peripheral artery disease and growing patient for kidney dialysis.

Bladder Scanners Market
https://www.delveinsight.com/report-store/bladder-scanners-market
"DelveInsight's 'Bladder Scanners Market Insight, Competitive Landscape and Market Forecast, 2030' report delivers an in-depth understanding of Bladder Scanners and the historical and forecasted Bladder Scanners market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Iga Nephropathy Market
https://www.delveinsight.com/report-store/iga-nephropathy-market
DelveInsight's "IgA Nephropathy Market Insights, Epidemiology and Market Forecast - 2032" report delivers an in-depth understanding of the IgA Nephropathy, historical and forecasted epidemiology as well as the IgA Nephropathy market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, Japan, and China.

Vutrisiran Market
https://www.delveinsight.com/report-store/vutrisiran-market
DelveInsight's "Vutrisiran Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Vutrisiran, historical and forecasted epidemiology as well as the Vutrisiran market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Gastroesophageal Reflux Disease Market
https://www.delveinsight.com/report-store/gastroesophageal-reflux-disease-gerd-market
DelveInsight's "Gastroesophageal Reflux Disease (GERD) Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Gastroesophageal Reflux Disease (GERD), historical and forecasted epidemiology as well as the Gastroesophageal Reflux Disease (GERD) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.